Compare ENVB & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENVB | NUWE |
|---|---|---|
| Founded | 1994 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0M | 2.9M |
| IPO Year | N/A | N/A |
| Metric | ENVB | NUWE |
|---|---|---|
| Price | $3.73 | $1.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $120.00 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 42.7K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $8,167,999.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.60 | $1.71 |
| 52 Week High | $96.30 | $70.14 |
| Indicator | ENVB | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 40.00 | 31.77 |
| Support Level | $4.90 | $1.71 |
| Resistance Level | $5.34 | $2.20 |
| Average True Range (ATR) | 0.85 | 0.17 |
| MACD | -0.29 | -0.04 |
| Stochastic Oscillator | 0.80 | 0.93 |
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.